BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 21, 2011
View Archived Issues
Johnson & Johnson recaps highlights of third quarter 2011
Read More
German research team presents new cyclin-dependent kinase 9 inhibitors
Read More
Ligand Pharmaceuticals and Sage Therapeutics enter licensing agreement
Read More
Analysis of TIRASMUS data identifies possible marker of temsirolimus efficacy in colorectal cancer
Read More
FDA accepts Lymphoseek NDA for review
Read More
Further phase I data reported on GDC-941 in metastatic and advanced cancer
Read More
New antibacterials show activity against Gram-positive and -negative pathogens
Read More
GlaxoSmithKline discloses new RIP-2 inhibitors
Read More
New agents for viral infections prepared by Vertex
Read More
Novel angiogenesis-promoting peptides patented in Korea
Read More
Dosing complete in phase II trial of oral PTH analogue in women with osteoporosis
Read More
Amicus closes recruitment in phase III Amigal study
Read More
Kinagen claims new protein kinase inhibitors
Read More
Promising 96-week data reported from phase II ocrelizumab trial in RRMS
Read More
FDA extends PDUFA date for Tysabri sBLA
Read More
Findings disclosed from ATON study evaluating atacicept in optic neuritis
Read More
Evotec and Apeiron Biologics collaborate on new target
Read More
Thrombogenics' ocriplasmin MAA accepted for review
Read More
Novel nitroxyl-releasing agents synthesized in U.S.
Read More
Isotechnika gives update on Luveniq strategy in Europe
Read More
Merck Serono to return full rights to Parkinson's disease candidate to Newron
Read More
OncoGenex Pharmaceuticals begins enrollment in OGX-427 study
Read More
Critical Outcome Technologies reports promising preclinical data on COTI-2
Read More
Protox Therapeutics' study of transrectal PRX-302 advances
Read More
EMA finds no link between cancer and use of angiotensin AT receptor antagonists
Read More